US 11,918,724 B2
Method for temporarily interrupting an extracorporeal blood treatment, control device and blood treatment apparatus
Uwe Hermann, Nuthetal (DE); Sabine Kipp, Bad Homburg (DE); Christine Nachbaur-Sturm, Hofheim a. Ts. (DE); Thomas Pusinelli, Altenstadt (DE); Martin Gruendken, Rosbach (DE); and Georg Verch, Wiesbaden (DE)
Assigned to Fresenius Medical Care Deutschland GmbH, Bad Homburg (DE)
Filed by Fresenius Medical Care Deutschland GmbH, Bad Homburg (DE)
Filed on Jun. 20, 2017, as Appl. No. 15/628,210.
Application 15/628,210 is a continuation of application No. 13/511,288, granted, now 9,713,670, previously published as PCT/EP2010/007074, filed on Nov. 23, 2010.
Claims priority of application No. 102009054415.1 (DE), filed on Nov. 24, 2009; and application No. 102010010928.2 (DE), filed on Mar. 10, 2010.
Prior Publication US 2017/0312418 A1, Nov. 2, 2017
Int. Cl. A61M 1/16 (2006.01); A61M 1/36 (2006.01); A61M 60/113 (2021.01); A61M 60/279 (2021.01); A61M 60/37 (2021.01); A61M 60/38 (2021.01); A61M 60/538 (2021.01); A61M 60/546 (2021.01); A61M 60/554 (2021.01); A61M 60/585 (2021.01); A61M 60/847 (2021.01); A61M 60/849 (2021.01); A61M 1/30 (2006.01); A61M 1/34 (2006.01)
CPC A61M 1/3653 (2013.01) [A61M 1/3656 (2014.02); A61M 60/113 (2021.01); A61M 60/279 (2021.01); A61M 60/37 (2021.01); A61M 60/38 (2021.01); A61M 60/538 (2021.01); A61M 60/546 (2021.01); A61M 60/554 (2021.01); A61M 60/585 (2021.01); A61M 60/847 (2021.01); A61M 60/849 (2021.01); A61M 1/1601 (2014.02); A61M 1/1605 (2014.02); A61M 1/30 (2013.01); A61M 1/305 (2014.02); A61M 1/34 (2013.01); A61M 1/3424 (2014.02); A61M 1/36 (2013.01); A61M 1/3643 (2013.01); A61M 1/3644 (2014.02); A61M 1/3646 (2014.02); A61M 1/3675 (2013.01); A61M 2205/3306 (2013.01); A61M 2205/50 (2013.01); A61M 2205/502 (2013.01); Y10T 137/0324 (2015.04)] 14 Claims
OG exemplary drawing
 
1. A control device configured: (i) to be activated or controlled in order to temporarily interrupt a blood treatment being effected by a blood treatment apparatus or (ii) to effect a temporary interruption of the blood treatment apparatus;
wherein the blood treatment apparatus is configured to be connected to a patient via an extracorporeal blood circuit during the blood treatment;
wherein the control device is configured to effectuate the blood treatment by activating a blood pump of the blood treatment apparatus to: (i) withdraw blood from the patient, (ii) convey the blood through the extracorporeal blood circuit, and (iii) return the blood to the patient;
wherein the control device is configured to transition the blood treatment apparatus into a state in which the blood treatment is temporarily interrupted while the blood treatment apparatus is disconnected from the patient and while blood of the patient remains in the extracorporeal blood circuit;
wherein the control device is configured to transition the blood treatment apparatus to subsequently continue the blood treatment after the state in which the blood treatment is temporarily interrupted, the blood treatment apparatus being reconnected to the patient prior to continuing the blood treatment;
wherein the control device is configured to, during the state in which the blood treatment is temporarily interrupted and while the blood treatment apparatus is disconnected from the patient and while the blood of the patient is remaining in the extracorporeal blood circuit, induce a first connection of an arterial line section of the extracorporeal blood circuit to a source of substituate and a second connection of a venous line section of the extracorporeal blood circuit to the source of substituate, or configured to advise a user to make the first connection of the arterial line section and the second connection of the venous line section of the extracorporeal blood circuit to the source of substituate;
wherein the control device is further configured to, during the state in which the blood treatment is temporarily interrupted and while the blood treatment apparatus is disconnected from the patient and while the blood of the patient is remaining in the extracorporeal blood circuit, activate the blood pump to induce or effect a circulation of at least one substituate liquid supplied from the source of substituate in the extracorporeal blood circuit;
wherein, in response to temporarily interrupting the treatment, the control device is configured to automatically change or deactivate, during the temporary interruption of the blood treatment, (i) threshold windows of parameters or (ii) monitoring processes, wherein the threshold windows of parameters or the monitoring processes are set or used during the blood treatment; and
wherein the control device is configured to automatically deactivate monitoring processes during the temporary interruption of the blood treatment.